https://investorshangout.com/ascendis-pharma-faces-fda-review-delay-for-transcon-cnp-therapy-473408-/
Ascendis Pharma's TransCon CNP therapy faces an unexpected FDA review delay, pushing the decision to 2026. Learn about the implications and updates here.
transcon cnpascendispharmafacesfda